Hikma Pharmaceuticals USA Inc. is recalling 382,775 vials of Lorazepam Injection (lorazepam), 2 mg/mL, because the product failed to meet specifications for impurities and degradation compounds. This voluntary recall affects cartons containing 25 vials (1mL each) that were distributed nationwide. Using medication that has degraded or contains excessive impurities can affect the safety and effectiveness of the drug.
Medications that exceed impurity specifications may not perform as intended or could potentially cause unexpected side effects. Because this medication is an injectable drug often used in clinical settings, maintaining high purity standards is critical for patient safety.
Manufactured by Hikma Berkeley Heights, NJ 07922; Recall #: D-0551-2025; Quantity: 382,775 1mL vials.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.